医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Nichi GLOW:来自日本的β-葡聚糖在自闭症谱系障碍儿童的临床研究中改善了行为、睡眠和肠道微生物群

2022年03月15日 PM04:16
このエントリーをはてなブックマークに追加


 

东京

(美国商业资讯)–发表在BMJ Neurology Open (http://dx.doi.org/10.1136/bmjno-2021-000203)上的开创性研究发现,自闭症谱系障碍(ASD)儿童在口服黑酵母菌AFO-202菌株产生的Beta 1,3 -1,6葡聚糖(Nichi GLOW)后,行为、学习技能和睡眠状况均有改善。据报道,Nichi GLOW还可对肠道微生物群进行有益重组,其来源、生产方法和纯度都与其他β葡聚糖不同。

本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20220313005038/zh-CN/

Improvement of learning and communication skills, sleep pattern and sleep quality beside peer interaction were the major changes observed in a clinical study after a 90-day consumption of Nichi GLOW beta glucan food supplement, according to the parents of study participants. One of them demonstrated his reading, writing and mathematical skills in a follow-up consulting with Dr Raghavan, developmental pediatrician & neurologist. ß-glucans considered clearing aggregated alpha-synuclein by enhancing NK cells & as a prebiotic, control enterobacteria, a cause of the disease, thus may have potentials in tackling neurological illnesses involving gut microbiome-dysbiosis. Nichi GLOW, a safe food supplement, which does not contain any allergens are worth larger clinical studies of longer follow-up in different populations to validate as an adjunct to conventional treatment in neurodevelopmental and neurodegenerative illnesses, as gut microbiota varies with food habits also, said Dr Raghavan. (Graphic: Business Wire)

Improvement of learning and communication skills, sleep pattern and sleep quality beside peer interaction were the major changes observed in a clinical study after a 90-day consumption of Nichi GLOW beta glucan food supplement, according to the parents of study participants. One of them demonstrated his reading, writing and mathematical skills in a follow-up consulting with Dr Raghavan, developmental pediatrician & neurologist. ß-glucans considered clearing aggregated alpha-synuclein by enhancing NK cells & as a prebiotic, control enterobacteria, a cause of the disease, thus may have potentials in tackling neurological illnesses involving gut microbiome-dysbiosis. Nichi GLOW, a safe food supplement, which does not contain any allergens are worth larger clinical studies of longer follow-up in different populations to validate as an adjunct to conventional treatment in neurodevelopmental and neurodegenerative illnesses, as gut microbiota varies with food habits also, said Dr Raghavan. (Graphic: Business Wire)

自闭症是一种神经发育障碍。在发达国家中,每44个儿童中就有一个受其影响。自闭症有多种病因,表现出的严重程度也各不相同。罹患自闭症的儿童在随后的生活中更有可能患上神经退行性疾病。在该研究中,摄入Nichi GLOW改善了CARS得分和沟通能力(https://www.youtube.com/watch?v=reJOjBMKSg4)。Nichi GLOW能够控制肠杆菌,这种肠道微生物群会产生形如纤维(curli)和淀粉样纤维(amyloid)的有害蛋白质,导致α-突触核蛋白在神经元中错误折叠和堆积,成为致病因素(https://doi.org/10.1101/2021.10.26.21265505)。主要研究者Raghavan博士表示,突触核蛋白病通过肠道-脑轴扩散到大脑,可能会导致帕金森病或阿尔茨海默病,因此,Nichi葡聚糖系列产品对神经退行性疾病的预防作用值得研究,其在大脑中的作用机制之一是激活小胶质细胞(https://doi.org/10.1016/j.jns.2021.117554)。

这些发现在自闭症周日(Autism Sunday) (https://www.ncrmniche.org/autismsunday2022/proceedings/index.html)活动相关的网络研讨会上被公布。自闭症周日活动由旨在纪念Jesuit Antonyraj的高级康复和教育跨学科中心(JAICARE)举办。科学家们评论称,在日本进行的研究揭开了这种ß-葡聚糖的隐藏潜力(https://doi.org/10.1101/2021.08.05.21261640);由于日本的健康生态系统有助于开发新型解决方案,再加上GN公司遍布全球的跨学科医疗保健专业知识网络,才使这一突破性的成果成为可能。 https://sponsored.bloomberg.com/article/jco/japan-where-high-tech-meets-high-value-foreign-direct-investment

Nichi葡聚糖系列产品于1996年在日本作为食品添加剂获得批准。它们不含任何普遍已知的过敏原。这种独一无二在葡聚糖产品作为一种胞外多糖在日本GMP认证的设施内通过新型的黑酵母菌菌株生产,并以Nichi-GLOW、Neu-REFIX、Nichi Glucan和Nichi Glucan-REFIX等品牌远销海外。该系列产品并非用于诊断、治疗、治愈或预防任何疾病,在各国的批准情况可能不同。对于具体健康问题,请咨询医师意见。

免责声明:本公告之原文版本乃官方授权版本。译文仅供方便了解之用,烦请参照原文,原文版本乃唯一具法律效力之版本。

在 businesswire.com 上查看源版本新闻稿: https://www.businesswire.com/news/home/20220313005038/zh-CN/

CONTACT

Samuel JK Abraham

info@gncorporation.com

 

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024